DOI: 10.25881/20728255_2026_21_4_59

Authors

Umarov G.M., Shestakov E.A., Fedyk O.V., Zhiburt E.B.

Pirogov National Medical and Surgical Center, Moscow

Abstract

Rationale: Hypofibrinogenemia (low fibrinogen concentration in the blood) interferes with proper blood clotting, leading to an increased risk of bleeding.

Objective: To determine the incidence of hypofibrinogenemia, its clinical manifestations, and the specifics of transfusion therapy for patients with hypofibrinogenemia in a multidisciplinary hospital.

Methods: A retrospective study, using electronic medical records, examined the incidence of hypofibrinogenemia (fibrinogen concentration ≤1.5 g/L), its clinical manifestations, and the specifics of blood component transfusion in patients with hypofibrinogenemia at the Pirogov Center in 2025.

Results: Among 43,987 patients, hypofibrinogenemia was recorded in 42 patients, including 26 (62%) women. Fatal outcomes were recorded in 2 patients (4.76%) with hypofibrinogenemia and, significantly less frequently, in 15 patients (0.03%) without hypofibrinogenemia (p<0.001). Hypofibrinogenemia was recorded once in 35 patients (83%). The number of hypofibrinogenemia determinations directly correlates with the INR and APTT maxima and vice versa – with the minima of hematological parameters. The proportion of transfusion recipients among patients with hypofibrinogenemia was 22.4% higher than among patients without hypofibrinogenemia (p<0.001). Cryoprecipitate is a drug for the correction of hypofibrinogenemia. At the Pirogov Center, it is commonly prescribed for bleeding in patients with a fibrinogen concentration of less than 1.5 g/L. In 2025, a total of 35 units of cryoprecipitate.

Conclusion: In 2025, hypofibrinogenemia was detected in 0.1% of hospitalized patients at the Pirogov Center. Hypofibrinogenemia is associated with increased in-hospital mortality and the frequency of blood transfusion therapy. In some cases, hypofibrinogenemia is an incidental finding that does not affect the course of the underlying disease and does not require specific interventions. Viscoelastic testing should be used to assess the clinical significance of hypofibrinogenemia. Donor cryoprecipitate remains the first-line treatment for hemostasis correction in hypofibrinogenemic bleeding.

Keywords: blood, fibrinogen, hypofibrinogenemia, blood transfusion, cryoprecipitate.

References

1. Shevchenko YL, Karpov OE, Zhiburt EB. Blood transfusion: history and modernity (on the 100th anniversary of blood transfusion in Russia). Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I. Pirogova. 2019; 14(4): 4-11. (In Russ.) doi: 10.25881/ BPNMSC.2020.29.78.001.

2. Zhiburt EB, Madzaev SR, Shestakov EA. Patient blood management. 2nd edition. M.: Pirogov National Medical and Surgical Center, 2021. (In Russ.)

3. Zhiburt EB, Chemodanov IG, Shestakov EA. Cryoprecipitate production in Russia: past, present and future. Gematologiya i Transfuziologiya. 2019; 64(1): 16-20. (In Russ.)

4. Zhiburt EB, Khamitov RG, Shestakov EA, et al. On the protocol of massive transfusion. Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I. Pirogova. 2025; 20(4): 129-135. (In Russ.) doi: 10.25881/20728255_2025_20_4_129.

5. Zhiburt EB, Madzaev SR, Shestakov EA. Medical and cost-effectiveness of a restrictive blood transfusion strategy. Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I. Pirogova. 2015; 10(1): 100-102. (In Russ.)

6. Shevchenko YL, Zhiburt EB, Shestakov EA. The implementation of a blood-saving ideology in the practice of the Pirogov Center. Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I.Pirogova. 2008; 3(1): 14-21. (In Russ.)

7. Pokhabov DS, Shestakov EA, Shalygin LD, Zhiburt EB. 20 years of blood service at the Pirogov Center. Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I. Pirogova. 2023; 18(2): 15-20. (In Russ.) doi: 10.25881/20728255_2023_18_2_15.

8. Kuznetsov SI, Shestakov EA, Gusarov VG, et al. Blood transfusion in a COVID-19 hospital. Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I. Pirogova. 2021; 16(4): 74-77. (In Russ.) doi: 10.25881/20728255_2021_16_4_74.

9. Zhiburt EB, Khamitov RG, Shestakov EA, et al. Transfusion correction of hemostasis in clinical guidelines “Acute promyelocytic leukemia”. Tromboz, gemostaz i reologiya. 2026; 1: 69-75. (In Russ.) doi: 10.25555/THR.2026.1.1182.

10. Pokhabov DS, Shestakov EA, Gusarov VG, et al. Scientific justification for the use of albumin in a multidisciplinary clinic. Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I. Pirogova. 2024; 19(4): 68-73. (In Russ.) doi: 10.25881/20728255_2024_19_4_68.

11. Pokhabov DS, Shestakov EA, Melnichenko VYa, et al. Scientific justification for the use of immunoglobulin in a multidisciplinary clinic. Vestnik Nacional’nogo mediko-hirurgicheskogo centra im. N.I. Pirogova. 2025; 20(2): 57-60. (In Russ.) doi: 10.25881/20728255_2025_20_2_57.

12. Zhiburt EB, Gilmutdinova IR, Kuzmin NS. Side effects of drugs on hematopoiesis and hemostasis. – M.: Pirogov National Medical and Surgical Center, 2015. (In Russ.)

13. Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med. 2016; 7: 217-225. doi: 10.2147/JBM.S90693.

14. Bor MV. Congenital fibrinogen disorders. Ugeskr Laeger. 2024; 186(1): V04230274. Danish. doi: 10.61409/V04230274.

15. Mohsenian S, Casini A, Peyvandi F. The thrombotic paradox in congenital fibrinogen deficiencies: from pathophysiology to practice. Res Pract Thromb Haemost. 2025; 9(5): 102979. doi: 10.1016/j.rpth.2025.102979.

16. Maier CL, Barker NA, Sniecinski RM. Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors. Anesth Analg. 2020; 131(2): e117-e119. doi: 10.1213/ANE.0000000000004949.

For citation

Umarov G.M., Shestakov E.A., Fedyk O.V., Zhiburt E.B. The problem of hypophibrinogenemia in clinical practice. Bulletin of Pirogov National Medical & Surgical Center. 2026;21(4):59-62. (In Russ.) https://doi.org/10.25881/20728255_2026_21_4_59